SuperworthZoetis Inc. ZTS
Drug Manufacturers - Specialty & Generic, Healthcare
$71.41
−0.20%
- Market cap
- $29.5B
- PE
- 11.8×
- 10y median 37.8×
- Forward PE
- Price to sales
- 3.1×
- EV/EBIT
- 10.5×
- Revenue, 12 months
- $9.5B
- +1% on a year ago
- Net margin
- 27.7%
- Free cash flow yield
- 7.8%
Zoetis trades at 11.8× trailing earnings, cheaper than 100% of the last ten years. Revenue was $9.5B over the last twelve months, up 1% on a year earlier with a 28% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.2B | $2.2B | $2.4B | $2.4B | $2.3B+5% | $2.2B+0% | $2.5B+5% | $2.4B+1% | $2.4B+3% | $2.3B+3% | $2.5B−0% | |
| Cost of revenue | $728M | $643M | $668M | $701M | $707M−3% | $618M−4% | $664M−1% | $672M−4% | $712M+1% | $641M+4% | $673M+1% |
| Gross profit | $1.5B | $1.5B | $1.7B | $1.7B | $1.6B+8% | $1.6B+2% | $1.8B+7% | $1.7B+2% | $1.7B+4% | $1.6B+3% | $1.8B−1% |
| R&D | $174M | $162M | $171M | $167M | $186M+7% | $157M−3% | $172M+1% | $170M+2% | $199M+7% | $180M+15% | $173M+1% |
| SG&A | $565M | $547M | $581M | $565M | $625M+11% | $574M+5% | $614M+6% | $571M+1% | $619M−1% | $588M+2% | $592M−4% |
| $709M | $801M | $906M | $920M | $765M+8% | $846M+6% | $989M+9% | $936M+2% | $826M+8% | $822M−3% | $937M−5% | |
| Interest expense | $59M | $62M | $63M | $61M | $56M−5% | $59M−5% | $58M−8% | $64M+5% | $57M+2% | $62M+5% | $61M+5% |
| Pre-tax income | $650M | $747M | $780M | $874M | $732M+13% | $773M+4% | $912M+17% | $914M+5% | $761M+4% | $758M−2% | $866M−5% |
| $127M | $148M | $156M | $182M | $151M+19% | $171M+16% | $186M+19% | $172M−6% | $158M+5% | $157M−8% | $175M−6% | |
| Net income | $525M | $599M | $624M | $682M | $581M+11% | $602M+1% | $726M+16% | $742M+9% | $603M+4% | $601M−0% | $691M−5% |
| $1.14 | $1.31 | $1.37 | $1.50 | $1.29+13% | $1.34+2% | $1.63+19% | $1.63+9% | $1.37+6% | $1.42+6% | $1.65+1% | |
| 460.1M | 458.8M | 456M | 453.5M | 451.1M−2% | 448M−2% | 445.5M−2% | 443.2M−2% | 438.6M−3% | 422.4M−6% | 417.7M−6% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Healthcare within ten times Zoetis's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ZTSZoetis Inc. | $29.6B | 11.8× | 37.8× | 3.1× | +1% | 27.7% | |
| GEHCGE HealthCare Technologies Inc. | $29.2B | 18.7× | 19.9× | 1.4× | +7% | 9.3% | |
| ALNYAlnylam Pharmaceuticals, Inc. | $30B | 37.8× | 121× | 6.3× | +95% | 16.1% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| DXCMDexCom, Inc. | $31.8B | 33.3× | 142× | 6.4× | +16% | 20.1% | |
| RMDResMed Inc. | $32.6B | 21.7× | 37.3× | 5.8× | +10% | 26.9% | |
| RPRXRoyalty Pharma plc | $32.6B | 30.2× | 27.6× | 12.9× | +10% | 32.0% | |
| BIIBBiogen Inc. | $32.8B | 39.3× | 16.1× | 3.3× | +0% | 8.3% | |
| WSTWest Pharmaceutical Services, Inc. | $25.8B | 46.9× | 45.8× | 7.8× | +12% | 17.0% | |
| LHLabcorp Holdings Inc. | $25.3B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.1B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| Peer median | $30.4B | 31.8× | 32.0× | 6.0× | +10% | 16.6% |
About
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .